WO2002002593A3 - Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof - Google Patents

Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof Download PDF

Info

Publication number
WO2002002593A3
WO2002002593A3 PCT/US2001/020849 US0120849W WO0202593A3 WO 2002002593 A3 WO2002002593 A3 WO 2002002593A3 US 0120849 W US0120849 W US 0120849W WO 0202593 A3 WO0202593 A3 WO 0202593A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
activity
angiogenesis
modulators
identification
Prior art date
Application number
PCT/US2001/020849
Other languages
French (fr)
Other versions
WO2002002593A2 (en
Inventor
Sivaram Pillarisetti
Itzhak D Goldberg
Original Assignee
Long Island Jewish Res Inst
Sivaram Pillarisetti
Itzhak D Goldberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Long Island Jewish Res Inst, Sivaram Pillarisetti, Itzhak D Goldberg filed Critical Long Island Jewish Res Inst
Priority to AU7785401A priority Critical patent/AU7785401A/en
Priority to EP01955795A priority patent/EP1355921A2/en
Priority to CA2452445A priority patent/CA2452445C/en
Priority to AU2001277854A priority patent/AU2001277854B2/en
Priority to JP2002507845A priority patent/JP4993834B2/en
Publication of WO2002002593A2 publication Critical patent/WO2002002593A2/en
Publication of WO2002002593A3 publication Critical patent/WO2002002593A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention is directed to small organic molecules and peptides having the ability to mimic or agonize hepatocyte growth factor/ scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer.
PCT/US2001/020849 2000-06-29 2001-06-29 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof WO2002002593A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU7785401A AU7785401A (en) 2000-06-29 2001-06-29 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
EP01955795A EP1355921A2 (en) 2000-06-29 2001-06-29 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
CA2452445A CA2452445C (en) 2000-06-29 2001-06-29 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
AU2001277854A AU2001277854B2 (en) 2000-06-29 2001-06-29 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
JP2002507845A JP4993834B2 (en) 2000-06-29 2001-06-29 Regulators of cell proliferation and angiogenesis, methods of use and identification thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60662800A 2000-06-29 2000-06-29
US09/606,628 2000-06-29
US27617001P 2001-03-15 2001-03-15

Publications (2)

Publication Number Publication Date
WO2002002593A2 WO2002002593A2 (en) 2002-01-10
WO2002002593A3 true WO2002002593A3 (en) 2003-08-07

Family

ID=28794211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020849 WO2002002593A2 (en) 2000-06-29 2001-06-29 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof

Country Status (5)

Country Link
EP (1) EP1355921A2 (en)
JP (1) JP4993834B2 (en)
AU (2) AU7785401A (en)
CA (1) CA2452445C (en)
WO (1) WO2002002593A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192976B2 (en) 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
PL1648998T3 (en) 2003-07-18 2015-03-31 Amgen Inc Specific binding agents to hepatocyte growth factor
CN100363383C (en) * 2003-07-21 2008-01-23 中国人民解放军军事医学科学院基础医学研究所 Micro-molecular polypeptides capable of combining with gold staphylococcus virulence factor regulatory protein and its pharmaceutical use
US7473682B2 (en) 2003-10-29 2009-01-06 Ramot At Tel Aviv University Ltd. Angiogenic peptides and uses thereof
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US7947682B2 (en) * 2004-12-29 2011-05-24 University Of Southern California Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents
WO2006091246A1 (en) * 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function
WO2006052840A2 (en) * 2004-11-04 2006-05-18 University Of Virginia Patent Foundation Bone tropic peptides
DK1846406T5 (en) 2005-02-09 2011-10-31 Arqule Inc Maleimide derivatives, pharmaceutical compositions and methods for the treatment of cancer
US7879898B1 (en) 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
US8236761B2 (en) 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
US7910555B2 (en) 2006-07-07 2011-03-22 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4 ) receptor ligands
WO2008047370A2 (en) 2006-10-19 2008-04-24 Ramot At Tel Aviv University Ltd. Compositions and methods for inducing angiogenesis
CA2704282A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
WO2009002807A2 (en) 2007-06-22 2008-12-31 Arqule, Inc. Indolyl pyrrolidines for the treatment of cancer
CN101801961B (en) 2007-06-22 2014-09-24 艾科尔公司 Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
US8247374B2 (en) 2007-11-09 2012-08-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
EP2313093A4 (en) * 2008-07-10 2012-03-28 Angion Biomedica Corp Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
EA201201273A1 (en) 2010-03-10 2013-02-28 Генмаб А/С MONOCLONAL ANTIBODIES TO C-MET
WO2012047826A2 (en) * 2010-10-05 2012-04-12 Angion Biomedica Corp. Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
JP2012193155A (en) * 2011-03-18 2012-10-11 Tohoku Univ Peptide capable of recognizing crystal surface of metal oxide nanoparticle
PL2810198T3 (en) 2012-01-30 2024-01-22 Universiteit Gent Anti-invasive compounds
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
JP2022520139A (en) 2018-10-12 2022-03-29 セラダプティブ インク Polypeptides containing β-tricalcium phosphate binding sequence and their use
EP3927702A4 (en) 2019-04-11 2022-05-11 Angion Biomedica Corp. Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
CN115317469A (en) * 2021-05-11 2022-11-11 四川大学 Application of leucoaphenanthrene C in preparation of medicine for preventing and/or treating breast cancer or breast cancer metastasis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006909A2 (en) * 1992-09-18 1994-03-31 United States Of America, As Represented By The Secretary, Department Of Health And Human Services A method of preventing tumor metastasis
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
WO1998000543A1 (en) * 1996-07-03 1998-01-08 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
WO2000077031A2 (en) * 1999-06-15 2000-12-21 University Health Network Muc1 ligands

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080068A1 (en) * 1998-03-12 2001-03-07 Novo Nordisk A/S Modulators of protein tyrosine phosphatases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006909A2 (en) * 1992-09-18 1994-03-31 United States Of America, As Represented By The Secretary, Department Of Health And Human Services A method of preventing tumor metastasis
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
WO1998000543A1 (en) * 1996-07-03 1998-01-08 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
WO2000077031A2 (en) * 1999-06-15 2000-12-21 University Health Network Muc1 ligands

Also Published As

Publication number Publication date
JP2005520480A (en) 2005-07-14
CA2452445A1 (en) 2002-01-10
JP4993834B2 (en) 2012-08-08
AU2001277854B2 (en) 2007-03-01
CA2452445C (en) 2011-02-15
WO2002002593A2 (en) 2002-01-10
EP1355921A2 (en) 2003-10-29
AU7785401A (en) 2002-01-14

Similar Documents

Publication Publication Date Title
WO2002002593A3 (en) Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
Haslik et al. First experiences with the collagen-elastin matrix Matriderm® as a dermal substitute in severe burn injuries of the hand
ATE468137T1 (en) INHIBITORS OF HMGB1 FOR THE TREATMENT OF TISSUE DISEASES
ATE336255T1 (en) HYALURONIC ACID ESTER FOR THE TREATMENT OF NORMOTROPHIC SKIN SCARS
CY1121447T1 (en) COMPOSITIONS FOR INCREASING TELEVISION ACTIVITY
EA200300536A1 (en) UNLIMITED SOMATIC STEM CELLS (USSC) RECEIVED FROM UMBILICAL HUMAN BLOOD
WO2005079822A3 (en) Pharmaceutical composition comprising a fibrin matrix and dermal fibroblasts for the treatment of wounds
EP1143943A3 (en) P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant
WO1999038952A3 (en) Cells or tissues with increased protein factors and methods of making and using same
DE60138549D1 (en) TOPICAL GEL DELIVERY SYSTEMS FOR THE TREATMENT OF SKIN DISEASES
WO2007038686A3 (en) Amniotic membrane preparations and purified compositions and methods of use
EP1295893A4 (en) SKIN TISSUE REGENERATION PROMOTERS COMPRISING GINSENOSIDE Rb1
EA200400482A1 (en) KERATINOCYCES SUITABLE FOR APPLICATION AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF THE RAS
IS2405B (en) Use of dextran sulphate to treat sudden blood-mediated inflammatory reaction (IBMIR)
DK1450771T3 (en) Pharmaceutical compositions for treating skin lesions and mucous membranes and methods and kits for their use
BR0010314B1 (en) aqueous solution for tissue and organ preservation.
ATE556134T1 (en) MESENCHYMA STEM CELLS AND USES THEREOF
Atiyeh et al. Improved healing of split thickness skin graft donor sites
CA2351947A1 (en) Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
MXPA02005069A (en) Tr3 specific binding agents and methods for their use.
NO20021410L (en) Prevention and treatment of blood coagulation-related diseases
ATE324905T1 (en) USE OF PLGF TO PREVENT OR TREAT SCHAEMIA OR STROKE
BR0308040A (en) Pharmaceutical and cosmetic compositions comprising plgf-1
ATE222501T1 (en) TISSUE FACTOR INFLUENCING VASCULAR FORMATION
Simman et al. Cultured palmar keratinocytes after auto-engraftment to plantar surface maintain site and function specificity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001277854

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001955795

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001955795

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2452445

Country of ref document: CA

WWG Wipo information: grant in national office

Ref document number: 2001277854

Country of ref document: AU